A PK/PD Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab-Treated non-small Cell Lung Cancer Patients
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A PK/PD Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab-Treated non-small Cell Lung Cancer Patients
Authors
Keywords
-
Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2018-07-30
DOI
10.1002/cpt.1198
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment
- (2017) James L. Gulley et al. JNCI-Journal of the National Cancer Institute
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment
- (2017) James L. Gulley et al. JNCI-Journal of the National Cancer Institute
- Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer
- (2016) M. Chatterjee et al. ANNALS OF ONCOLOGY
- Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling
- (2016) CH Li et al. CTS-Clinical and Translational Science
- Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities
- (2016) KM Morrissey et al. CTS-Clinical and Translational Science
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1
- (2016) Joohee Sul et al. ONCOLOGIST
- PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
- (2016) Claud Grigg et al. Journal for ImmunoTherapy of Cancer
- Immuno-oncology combinations: raising the tail of the survival curve
- (2016) Samuel J. Harris et al. Cancer Biology & Medicine
- Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25
- (2015) Dalil Hannani et al. CELL RESEARCH
- Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab
- (2015) C. Gebhardt et al. CLINICAL CANCER RESEARCH
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-L1 Inhibition With MPDL3280A for Solid Tumors
- (2015) Edward Cha et al. SEMINARS IN ONCOLOGY
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Pretreatment Serum VEGF Is Associated with Clinical Response and Overall Survival in Advanced Melanoma Patients Treated with Ipilimumab
- (2014) J. Yuan et al. Cancer Immunology Research
- Population pharmacokinetic-pharmacodynamic modelling in oncology: a tool for predicting clinical response
- (2013) Brendan C. Bender et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Single-Center Experience With Ipilimumab in an Expanded Access Program for Patients With Pretreated Advanced Melanoma
- (2013) Sofie Wilgenhof et al. JOURNAL OF IMMUNOTHERAPY
- Mutational heterogeneity in cancer and the search for new cancer-associated genes
- (2013) Michael S. Lawrence et al. NATURE
- Interleukin-18, more than a Th1 cytokine
- (2013) Daniela Novick et al. SEMINARS IN IMMUNOLOGY
- Rational combinations of immunotherapeutics that target discrete pathways
- (2013) Stefani Spranger et al. Journal for ImmunoTherapy of Cancer
- Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models
- (2011) Martin Bergstrand et al. AAPS Journal
- Development of a modeling framework to simulate efficacy endpoints for motesanib in patients with thyroid cancer
- (2010) Laurent Claret et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial
- (2010) B. C. Carthon et al. CLINICAL CANCER RESEARCH
- Elucidation of Relationship Between Tumor Size and Survival in Non-Small-Cell Lung Cancer Patients Can Aid Early Decision Making in Clinical Drug Development
- (2009) Y Wang et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor Dynamics
- (2009) Laurent Claret et al. JOURNAL OF CLINICAL ONCOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now